STAT

Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

Disappointing clinical trial results from Sanofi and Regeneron raise questions about the future role that certain drugs might have in treating asthma and other inflammatory related diseases.
Source: Kristoffer Tripplaar/Sipa via AP

Sanofi (SNY) and Regeneron Pharmaceuticals () said Friday that a monoclonal antibody drug targeting a protein called IL-33 provided no additional benefit to asthma patients when added to the already approved drug Dupixent.

Anda sedang membaca pratinjau, daftarlah untuk membaca selengkapnya.

Lainnya dari STAT

STAT2 mnt membacaPolitics
Biden Puts Forth An Elaborate — And Aggressive — Plan To Lower Drug Prices
His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date. 
STAT10 mnt membacaPolitics
How Pharma, Under Attack From All Sides, Keeps Winning In Washington
It’s all President Trump and Democrats on Capitol Hill can agree on. So why hasn’t Washington lowered drug prices?
STAT3 mnt membaca
Opinion: I Get Asked A Lot About Longevity. It Helps That I’m 104
As scientists pursue longevity and anti-aging research, we wanted to hear from a centenarian on her life experience and thoughts on aging. So we called one.